GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2009

Ferring Approved to Commercialize Prostate Cancer Drug within EU

Ferring Approved to Commercialize Prostate Cancer Drug within EU

Ferring will commercialize Firmagon in EU

  • Ferring Pharmaceuticals received authorization from the European Commission to market Firmagon, a prostate cancer drug. The treatment is a gonadotropin-releasing hormone receptor antagonist, indicated for patients with advanced, hormone-dependent prostate cancer. It is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen.

    The authorization follows degarelix' FDA approval in December 2008.

    In Phase III trials, Firmagnon reportedly reduced the levels of testosterone in more than 96% of patients within three days. Results were close to the immediate effect achieved with surgery, explains Ferring.
    ADNFCR-2184-ID-19038444-ADNFCR



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?